2023-01-25 07:00:00

Lysogene: Conversion of the Safeguard Proceedings Into Reorganization Proceedings

Logo Benzinga
Benzinga
By Business Wire

Regulatory News:

Lysogene (FR0013233475 LYS) LYS, a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces the conversion of the safeguard proceedings which has been in place since December 13, 2022 into reorganization proceedings.

As announced on January 6, 2023, in the absence of a solution to strengthen its financial situation and secure its cash runway during the safeguard proceedings, Lysogene together with the judicial administrator, filed a request with the Commercial Court of Nanterre for the conversion of the safeguard proceedings into reorganization proceedings. This request was examined and approved by the Commercial Court of Nanterre at the hearing of January 24, 2023.

In this context, Lysogene reminds that a bidding process for the purpose of finding buyers or investors has been published by the judicial administrator on January 6, 2023 and that the deadline for the submission of offers has been set by the latter to February 15, 2023 at 12:00 am.

Continue read on benzinga.com

Logo GlobeNewswire
SciencePress Release2023-01-24 21:01:00
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers...

Logo PR Newswire
TORONTO, Jan. 24, 2023 /CNW/ - Lysander Funds Limited ("Lysander") announces the January, February, and March 2023 cash distributions for each of...

Logo GlobeNewswire
SciencePress Release2023-01-24 16:45:00
CONVERSION OF THE RECEIVERSHIP PROCEEDINGS INTO JUDICIAL LIQUIDATION PROCEEDINGS DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 23:46:00
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the stock of Bioventus Inc....

Logo Benzinga
Business / FinanceBy Business Wire2023-01-06 16:21:00
Regulatory News: Lysogene (FR0013233475 LYS) LYS, a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that it...

Logo GlobeNewswire
SciencePress Release2023-01-24 21:15:00
LAVAL, Québec, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 12:36:00
Treatment IDE Will Provide Opportunity to Treat Additional Patients in the US SAN RAMON, Calif., Jan. 24, 2023 /PRNewswire/ -- BioVentrix, Inc., a privately...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 03:13:00
Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 14:01:00
Robbins Geller Rudman & Dowd LLP announces that purchasers of Y-mAbs Therapeutics, Inc. YMAB common stock on the open market, or pursuant to Registration...

Logo PR Newswire
HealthPress Release2023-01-25 00:18:00
SEATTLE, Jan. 24, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 06:00:00
Following expiration of Hart-Scott-Rodino waiting period regarding expansion of their collaboration on NK cell engagers, the licensing agreement between...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
BOSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS)...

Logo PR Newswire
TechnologyPress Release2023-01-24 14:00:00
Aetion and FDA will use the Aetion Evidence Platform ® to study crucial oncology research questions to advance the mission of the Oncology Center of...

Logo PR Newswire
HealthPress Release2023-01-24 13:00:00
FDA's Decision Forthcoming for Innovative Test with Agency's Breakthrough Device Designation ST. LOUIS, Jan. 24, 2023 /PRNewswire/ -- Geneoscopy Inc., a life...

Logo PR Newswire
HealthPress Release2023-01-24 12:36:00
Treatment IDE Will Provide Opportunity to Treat Additional Patients in the US SAN RAMON, Calif., Jan. 24, 2023 /PRNewswire/ -- BioVentrix ®, Inc., a...

Logo PR Newswire
NEW YORK, Jan. 24, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Y-mAbs...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 12:45:00
Phase 1/2 clinical trial expected to launch in early 2023 and will evaluate safety and preliminary impact on disease activity of IMPT-314 WEST HILLS, Calif.,...

Logo PR Newswire
HealthPress Release2023-01-24 17:14:00
Submission of EXXUA (gepirone HCl), a novel targeted single serotonin receptor agonist for treatment of Major Depressive Disorder receives PDUFA action date...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the Company, Finch, or Finch Therapeutics) (Nasdaq: FNCH) today...

Logo GlobeNewswire
SciencePress Release2023-01-24 21:25:00
REDWOOD CITY, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing...